{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:11:57Z","timestamp":1771881117124,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.atherosclerosis.2011.12.011","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T02:02:14Z","timestamp":1325642534000},"page":"471-477","source":"Crossref","is-referenced-by-count":12,"title":["Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program"],"prefix":"10.1016","volume":"221","author":[{"given":"Evan A.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Vidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie A.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Anzalone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Cressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 8A","key":"10.1016\/j.atherosclerosis.2011.12.011_bib0015","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"Suppl. 5A","key":"10.1016\/j.atherosclerosis.2011.12.011_bib0020","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/S0002-9149(01)01455-2","article-title":"Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin","volume":"87","author":"Olsson","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000077704","article-title":"Rosuvastatin-induced arrest in progression of renal disease","volume":"102","author":"Vidt","year":"2004","journal-title":"Cardiology"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd","year":"2007","journal-title":"Cardiology"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2007.07.004","article-title":"Comparison of short-term renal effects and efficacy of rosuvastatin 40mg and simvastatin 80mg, followed by assessment of long-term renal effects of rosuvastatin 40mg, in patients with dyslipidemia","volume":"1","author":"Stein","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0045","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2215\/CJN.09091010","article-title":"The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients","volume":"6","author":"Olyaei","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0050","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis","volume":"111","author":"Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0055","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0021-9150(01)00545-7","article-title":"Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose","volume":"160","author":"Chen","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/HJH.0b013e32831ef369","article-title":"Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion","volume":"27","author":"Park","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0070","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2353\/ajpath.2007.060882","article-title":"Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats","volume":"170","author":"Gianella","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0080","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease","volume":"14","author":"Tonelli","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0085","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2011.12.011_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005019.pub3","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of lipid reduction on the progression of renal disease: a meta-analysis","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0100","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0105","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0115","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjcard.2004.06.049","article-title":"Safety of rosuvastatin","volume":"94","author":"Shepherd","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0120","first-page":"A0828","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine","volume":"11","author":"Levey","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1098-2825(1998)12:5<280::AID-JCLA5>3.0.CO;2-A","article-title":"Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods","volume":"12","author":"Pugia","year":"1998","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pds.2032","article-title":"Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiologic programme comparing rosuvastatin with other marketed statins","volume":"19","author":"Garcia Rodriguez","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/pds.1281","article-title":"The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy","volume":"15","author":"McAfee","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0140","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2011.12.011_bib0145","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011011580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011011580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T03:56:11Z","timestamp":1543290971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915011011580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0021915011011580"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}